Menu ×


Congenital Anomalies Treatment Market Segmentation by Type (Congenital Heart Disease, Down Syndrome, Cleft Lip and Cleft Palate, Club Foot, Phenylketonuria, Edward’s Syndrome, and Others); by Treatment (Surgery, Additional Therapy, Drugs, and Others); and by End-Users (Hospitals, Specialty Clinics, and Others) – Global Demand Analysis & Opportunity Outlook 2031

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • December 20, 2021: Merck KGaA announced the acquisition of Chord Therapeutics to expand its neuro-inflammatory pipeline, to develop cladribine drug.

  • December 01, 2020: Fresenius Kabi launched a new Icatibant injection to treat acute attacks of hereditary angioedema in adults. Icatibant injection is an FDA-approved, cost-effective and quick-relief alternative to treat attacks of hereditary angioedema (HAE).

Global Congenital Anomalies Treatment Market Highlights over 2022 – 2031

The global congenital anomalies treatment market is estimated to grow at a CAGR of ~10% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the increasing prevalence of congenital anomalies amongst new born babies. Congenital anomalies or abnormalities can be caused due to various factors, including genetic makeup, environmental, socioeconomic or demographic factors, poor maternal nutritional status, and infections caught during pregnancies. According to the data by the World Health Organization (WHO), 295,000 newborns die within 28 days of birth every year, due to congenital anomalies, globally. Moreover, prevention of these anomalies is near to impossible, as the causes are vague and uncontrollable. A WHO report stated that over 50% of all congenital anomalies cannot be linked to a specific cause. As a result, treatment is the only solution for congenital abnormalities, leading to a high demand for treatment, which is estimated to boost the market growth. Furthermore, growing healthcare awareness amongst the parents, along with availability of advanced treatment options are anticipated to further propel the market growth.    

Congenital Anomalies Treatment Market

In addition to this, the increasing government investment in the field of medical research, is projected to further propel the market growth. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018. 

Reaseach & Development Expenditure  (% of GDP), 2016-2018

The market is segmented by treatment into surgery, additional therapy, drugs, and others, out of which, the surgery segment is anticipated to hold the notable share in the global congenital anomalies treatment market over the forecast period owing to the high success rate of surgeries. Moreover, surgeries guarantee permanent cure for congenital heart disease, cleft palate, and other disorders, which is estimated to boost the segment growth. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita, (USD), 2015-2018

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Congenital Anomalies Treatment Market Regional Synopsis

On the basis of geographical analysis, the global congenital anomalies treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of advancements in the healthcare sector, backed by rising healthcare expenditure across the region.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the high prevalence of congenital diseases in infants in the region. As per the data by the Center of Disease Control and Prevention (CDC), one in every 33 babies or about 3% of all babies born in the United States suffer from birth defects each year.

Congenital Anomalies Treatment Market Share

The global congenital anomalies treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global congenital anomalies treatment market includes the following segments:

By Type

  • Congenital Heart Disease
  • Down Syndrome
  • Cleft Lip and Cleft Palate
  • Club Foot
  • Phenylketonuria
  • Edward’s Syndrome 
  • Others

By Technology

  • Surgery
  • Additional Therapy
  • Drugs
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

Growth Drivers

  • Increasing Prevalence of Congenital Anomalies
  • Growing Health Awareness amongst Individuals


  • High Cost of Defect Screening
  • High Treatment Cost and Unfavorable Healthcare Policies

Top Featured Companies Dominating the Market

  • Johnson & Johnson Services, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • GlaxoSmithKline plc.
  • Regeneron Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • Amgen Inc.
  • Alexion Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis International AG
  • Ipsen Pharma
  • Fresenius Kabi USA


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved